Details for Patent: 10,307,419

Which drugs does patent 10,307,419 protect, and when does it expire?

Patent 10,307,419 protects REXULTI and is included in one NDA.

Protection for REXULTI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in thirty-one countries.

Summary for Patent: 10,307,419

Patent landscape, scope, and claims:

Title:	Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Abstract:	This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl -piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4 -yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
Inventor(s):	Inoue; Yoshiharu (Osaka, JP)
Assignee:	OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:	15/713,427
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,307,419
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,307,419

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-001	Jul 10, 2015		RX	Yes	No					Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-002	Jul 10, 2015		RX	Yes	No					Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-003	Jul 10, 2015		RX	Yes	No					Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-004	Jul 10, 2015		RX	Yes	Yes					Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-005	Jul 10, 2015		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 10,307,419

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2011-227057	Oct 14, 2011

International Family Members for US Patent 10,307,419

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	088319
Australia	2012321723
Brazil	112014008603
Canada	2851588
Chile	2014000909